Pfizer AG - Vyndaqel 61 mg, Weichkapseln | | 67518 | | 01 | | Vyndaqel 61 mg | | Weichkapseln | | N07XX08 | | Tafamidis | | 05.03.2020 | | |
| Composition | tafamidisum 61 mg, macrogolum 400, polysorbatum 20, povidonum K 90, E 321, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (rubrum), Drucktinte: macrogolum 400, polyvinylis acetas phtalas, E 171, propylenglycolum, pro capsula. | Packungsbestandteile | | Soft capsules | | | Active Agent | Dose |
---|
Tafamidisum | 61 mg |
| BAG: Active Agent | Dose |
---|
Tafamidisum | 61 mg |
| | Inactive agents | Dose | additional_information |
---|
(Rubrum) | | | E 171 | | color. | E 172 | | color. | E 321 | | | Gelatina | | Kapselhülle | Glycerol | | | Macrogol | 400 | Drucktinte | Polysorbatum 20 | | | Polyvinylis Acetas Phtalas | | | Povidonum K | 90 | | Pro Capsula | | | Propylenglycol | | | Sorbitolum Liquidum Partim Deshydricum | | |
| |
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
001 | 30 | 9422.28 | 9975.05 | B | SL | Yes |
|
|